Navigation Links
BeneChill Raises $13.5 Million Series C
Date:7/20/2009

SAN DIEGO, July 20 /PRNewswire/ -- BeneChill (www.benechill.com) - a privately held medical device company that concentrates on developing products in the therapeutic hypothermia arena with a focus on rapid, non-invasive cooling for use in the field - today announced it has closed a $13.5 million Series C financing. New investor HealthCap (Stockholm) led the financing. Series A and B investors MedVenture Associates, NGN Capital, and the Solon Foundation also participated. Proceeds will be used to fund early commercialization of the company's RhinoChill device.

Concurrent with the Series C financing, Johan Christenson of HealthCap joined the BeneChill Board of Directors.

BeneChill has recently completed its randomized PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study of the RhinoChill device in cardiac arrest patients. This study will determine whether the addition of intra-nasal cooling during resuscitation improves outcome following cardiac arrest over hospital-based cooling alone. Results of the PRINCE trial will be announced at the American Heart Association's Scientific Sessions in Orlando, Florida in November, 2009.

About the RhinoChill device

The RhinoChill device is non-invasive, portable, easy-to-use and does not require an external source of power for cooling. The device consists of a nasal catheter which delivers a proprietary inert coolant to the nasopharynx in patients requiring hypothermia. Hypothermia is currently used in patients with cardiac arrest, stroke or head injury. Unlike other cooling devices, the RhinoChill device is easily utilized in emergency field settings. The RhinoChill System is an investigational device in the United States, and is limited by US law to investigational use only. The company received a CE Mark for the RhinoChill device in 20
'/>"/>

SOURCE BeneChill
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. BeneChill Launches European Study of Intra-Arrest Cooling
2. BeneChills RhinoChill System Receives CE Marking for European Commercial Sale
3. National Advocacy Organization Representing Home Oxygen Patients Praises Introduction of Medicare Home Oxygen Therapy Act
4. American Chemical Society praises nomination of Collins as NIH Director
5. Stem Cell Industry Expert Praises, Encourages Continued Progress on Legislation to Promote Benefits of Cord Blood
6. Lung Cancer Alliance Praises Congresswoman Donna Christensen for Introduction of Legislation to Correct Healthcare Disparities
7. Hyperion Therapeutics Raises $60 Million Series C
8. Cytox Raises Pre-Series A Financing From Management and Existing UK Investors, Welcomes First US Investors
9. Obesity Greatly Raises Endometrial Cancer Risk
10. Transcend Medical Raises $35 Million Series B Round Towards Development of Novel Glaucoma Treatment
11. EUROPACE raises remote monitoring profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... VIENNA, Austria (PRWEB) March 04, 2015 ... to reduce subjectivity in density assessment and help ... focus of numerous abstracts accepted for presentation at ... 3-8, 2015. Ten abstracts - eight posters ... of Volpara Solutions’ automated breast density and quantitative ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... The print component of “Organic Living” ... Chronicle with a circulation of approximately 173,000 copies and ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... composed of heat-dried microbes that have digested the organic ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... $236.8 billion in 2014 and is estimated to ... CAGR of 4.0% from 2014 to 2019. , ... Gas Market for an analysis of industry trends, ... The global liquefied petroleum gas market is classified ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Specialized one- and two-year Indiana University graduate ... number of health information technology specialists in Indiana ... thanks in part to Recovery Act funding. Two ... learning opportunities. In collaboration with the Regenstrief ...
... HIV could help to develop a vaccine to build antibodies, ... has found. By investigating the action of the human ... to identify that the virus evolves to evade or ,escape, ... Melbourne and one of the senior authors on the paper ...
... pylori , a common stomach bacteria, minimizes the effects of ... of Michigan Medical School scientists. The study published in ... of investigators assembled by senior author John Y. Kao, M.D. ... professor in U-M,s Department of Internal Medicine. The findings indicate ...
... 4, 2011) Autism Speaks, the world,s largest autism ... announced the top awards for "Autism Connects", the international ... by student competitors selected by a juried panel demonstrate ... (ASD) to better connect with the world around them, ...
... 5 (HealthDay News) -- In people with advanced kidney cancer, ... is working, with high blood pressure linked to longer survival, ... of 544 people being treated with the drug sunitinib (Sutent) ... maximum systolic blood pressure reached 140 mmHg or higher survived ...
... New Rochelle, NY, May 5, 2011When children or adolescents ... the disorder, it may impair their ability to manage ... asthma-related anxiety is described in an article in ... published by Mary Ann Liebert, Inc. The article is ...
Cached Medicine News:Health News:IU-Regenstrief programs targeted to alleviate shortage of health IT workforce 2Health News:DNA from common stomach bacteria minimizes effects of colitis, U-M study says 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Blood Pressure May Hint at Kidney Cancer Outcome 2
(Date:3/4/2015)... 2015 UPM Pharmaceuticals, a division of Gregory ... Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has ... first drug approved to treat hypoactive sexual desire disorder ... The tablets will be manufactured at UPM,s ... . Dr. John M. Gregory ...
(Date:3/4/2015)... March 4, 2015 From March 8-11, ... 2015 Distribution Management Conference and Expo in ... HDMA,s largest supply chain education event, attended by ... who keep the pharmaceutical distribution industry moving. Attracting ... and legislative issues important to healthcare distribution and ...
(Date:3/4/2015)... 4, 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer ... and cancer, today announced that James A. Joyce ... corporate overview at the 27th Annual ROTH Conference on ... Laguna Niguel, California . To learn more ... A live webcast of the presentation will ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... Biosciences, Inc., a privately held company leading the ... announces one poster presentation and two oral presentations ... meeting on November 14, 2011 during the 9:00 ... presentations highlight results from Regado,s pipeline of antithrombotic ...
... GenturaDx today announced that it will present data from alpha ... Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 ... Of Assay Performance Between Cell Culture And A Rapid Automated ... will address the capability of the GenturaDx IDbox™ System to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: